Work

Continuous Interstitial Glucose Monitoring througha Long-Term Subcutaneous Implantable Sensorduring Pregnancy in Type 1 Diabetes: A Two-Patient Case Report

Year: 2025

Type: article

Abstract: INTRODUCTION: Optimal glycaemic control is crucial during pregnancy in women with type 1 diabetes mellitus (T1D). Current guidelines, based on positive data from the CONCEPTT (Continuous Glucose Monitoring in Pregnant Women With Type 1 Diabetes Trial), on maternal glycaemic control and fetal outcomes, recommend offering real-time Continuous Glucose Monitoring (rt-CGM) as a standard method in all pregnancies of women with type 1 diabetes (T1D). CASE PRESENTATION: In these two clinical cases, we describe for the first time the gestational outcomes in two patients with T1D who chose to maintain a long-term implantable subcutaneous sensor (Eversense XL®) as a CGM method during their pregnancies. The first case concerns a 33- year-old young woman with a 25-year history of T1D on Continuous Subcutaneous Insulin Infusion (CSII), who faced her first pregnancy with a suboptimal preconception glycaemic control; the second case describes the second pregnancy of a 37-year-old patient with a more recently diagnosed T1D, on multiple daily injection (MDI) therapy who achieved adequate glycaemic compensation before planned conception. CONCLUSION: trimester, respectively, without any complications, allowing optimal monitoring and adjustment of insulin dose and achieving optimal glucose targets throughout the pregnancy until delivery.

Source: Endocrine Metabolic & Immune Disorders - Drug Targets

DOI: 10.2174/0118715303393466250807050121